LGD-4033 vs RAD-140 (Testolone)
A side-by-side research comparison of LGD-4033 and RAD-140 (Testolone) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LGD-4033 | RAD-140 (Testolone) |
|---|---|---|
| Full name | Ligandrol (LGD-4033) | Testolone (RAD-140) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Investigational (not approved; banned in sport) |
| Mechanism | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. | Acts as a strong, tissue-selective androgen receptor agonist in muscle and bone, driving anabolic signaling with a higher anabolic-to-androgenic ratio than testosterone in preclinical models. |
| Molecular weight | 338.25 Da | 393.83 Da |
| Half-life | ~24-36 hours | ~16-20 hours |
| Bioavailability | ~90% oral | Oral |
| Typical dose | 5-10 mg | Commonly cited 5-15 mg/day (research) |
| Frequency | Once daily | Once daily |
| Route | Oral | Oral |
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
RAD-140 (Testolone) reported benefits
- Strong lean muscle gains (research)
- Increased strength
- Studied originally for muscle wasting and breast cancer
- Bone-supportive signaling
Related comparisons
Research and educational reference only. Not medical advice.